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reported knee pain and clinical knee osteoar-
thritis: The Maastricht StudyIntroduction
Osteoarthritis (OA) of the knee is a progressive disabling joint
disease characterized by pain and functional limitations. The
global age-standardized prevalence of radiographic knee OA in
2010 was estimated to be 3.8%, and was higher in women (4.8%)
than in men (2.8%) [1].
Several epidemiological studies have identified a strong
association between type 2 diabetes mellitus (T2DM) and knee
OA [2,3]. As both diseases share overweight and obesity as strong
common risk factors, one of the main underlying mechanisms
causing OA in T2DM patients is thought to be the increased
mechanical load on weight-bearing joints, especially the knees.
However, the above-mentioned studies have shown that T2DM
may be an independent risk factor for OA, suggesting a coexisting
metabolic cause. Conversely, other studies have reported no
independent association between T2DM and OA [4,5].
The mechanisms underlying pain in knee OA are still poorly
understood. Perception of pain in patients with T2DM might be
different partly because of their different underlying biopathology
(formation of neurovascular channels in subchondral bone and
articular cartilage, low-grade inflammation) and partly related to
diabetic neuropathy. Therefore, it would be of value to understand
whether the level of knee pain experienced by patients with T2DM
is different from that of those without T2DM.
Thus, the primary aim of the present study was to evaluate the
association of T2DM with knee pain and clinical knee OA. In
addition, a further aim was to determine whether patients with
T2DM experience different levels of pain compared with people
without T2DM.
Methods
The Maastricht Study is an observational, prospective, popula-
tion-based cohort study, the details of which have been published
elsewhere [6]. The present report includes cross-sectional data
from the first 3451 participants who completed the baseline
survey between November 2010 and September 2013. The study
has the approval of the institutional medical ethics committee
(NL31329.068.10) and Dutch Ministry of Health, Welfare and Sport
(Permit 131088-105234-PG). All participants gave their written
informed consent. Information regarding drug use was available
from electronic dispensing records obtained from community
pharmacies. Participants not consenting to collection of their
pharmacy data (n = 163), and those with type 1 diabetes mellitushttps://doi.org/10.1016/j.diabet.2018.01.013
1262-3636/C 2018 Elsevier Masson SAS. All rights reserved.(T1DM; n = 43) or missing data for any of the covariates (n = 507),
were excluded, leaving a total of 2738 participants (Fig. 1).
Glucose metabolism status was defined, as per the World
Health Organization (WHO) 2006 criteria, by a 2-h oral glucose
tolerance test (OGTT) after an overnight fast. In addition,
participants taking an antihyperglycaemic drug [AD; Anatomical
Therapeutic Chemical Classification System (ATC) code A10] [7]
were categorized as T2DM patients regardless of glucose levels.
The date of the OGTT was used as the date of inclusion. T2DM
patients were stratified by HbA1c ( 6.0%, 6.1–7.0%, > 7.0%) and by
duration of AD treatment.
The presence of knee pain was assessed by simply asking
participants whether their knee pain, which could not be due to an
accident, was present for at least four of the previous six weeks
(yes/no). Clinical knee OA was defined based on a modified version
of the American College of Rheumatology (ACR) guidelines (Table
S1; see supplementary materials associated with this article
online) [8]. Participants should have experienced knee pain, and at
least three of the following five criteria should apply:
age > 50 years; morning stiffness (lasting < 30 min); bony tender-
ness; bony distortion; and no palpable warmth in the knee. In
addition, participants with knee prostheses were classified as
having knee OA. Severity of knee pain was scored on a visual
analogue scale (VAS) ranging from 0 to 10, with 0 corresponding to
‘‘no pain’’ and 10 reflecting ‘‘pain as bad as it possibly could be’’.
Subjects missing data for any outcome were excluded from
analyses of that outcome, thereby leaving a final total n = 2719 for
knee pain analysis and n = 2721 for knee OA analysis (Fig. 1).
Logistic regression models were fitted to test the association
between T2DM and knee pain or clinical knee OA. Odds ratios (ORs)
and 95% confidence intervals (CIs) were assessed in unadjusted
models and in models adjusted for body mass index (BMI).
Subsequently, our analyses were also adjusted for age, gender and
BMI. Finally, our fully adjusted models included the following
confounders: age, gender, BMI, systolic (SBP) and diastolic blood pressure
(DBP), smoking status, level of education, alcohol use, a
physically demanding occupation and a history of activities
such as running and/or jumping; and use of the following drugs in the six months prior to
inclusion: statins, diuretics, calcium-channel blockers, beta-
blockers, renin–angiotensin–aldosterone system (RAAS) inhibi-
tors, paracetamol, non-steroidal anti-inflammatory drugs
(NSAIDs), opioids, bisphosphonates and systemic corticoids.
The association of T2DM with severity of self-reported knee
pain in patients with clinical knee OA was assessed using a linear
regression model, adjusted for the same above-mentioned
confounders as in the fully adjusted logistic regression model
and complemented by the following covariates: previous knee
[(Fig._1)TD$FIG]
Fig. 1. Flow chart of inclusion of study participants.
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pathic pain [four-item Neuropathic Pain Questionnaire (DN4)
score  3], and knee alignment (valgus/varus). Statistical signifi-
cance was set at P < 0.05, and SAS version 9.4 software (SAS
Institute, Cary, NC, USA) was used for all analyses.
Results
From the study base population of 3451 participants, 2719 and
2721 cases with no missing data were available for the knee pain
and knee OA analyses, respectively (Fig. 1). For the former analysis,
549/2719 (20.2%) subjects fulfilled the case definition, as did 387/
2721 (14.2%) subjects for the latter analysis (Table S2; see
supplementary materials associated with this article online).
Participants with knee pain were, on average, 1 year older than
those without knee pain (60.6 vs 59.8 years), whereas participants
with knee OA were, on average, two years older than those without
knee OA (62.3 vs 59.6 years). Also, participants with knee OA or
knee pain had higher BMI scores than those without knee OA orknee pain. The age and gender standardized rate of OA in T2DM
patients was 21.5/100 population compared with 12.4/100
population without T2DM. The age and gender distribution of
the population without T2DM was used as reference (results not
shown).
Compared with having normal glucose metabolism (NGM),
T2DM was not associated with knee pain after adjusting for all
relevant confounders (OR: 0.89, 95% CI: 0.67–1.19). Stratification
of T2DM patients by HbA1c or duration of AD use showed similar
results (Table S3; see supplementary materials associated with this
article online). Similarly, T2DM was not associated with knee OA
after adjusting for BMI (OR: 1.22, 95% CI: 0.94–1.60). In addition,
after adjusting for other relevant confounders, T2DM results
showed no relevant changes (OR: 0.96, 95% CI: 0.69–1.33).
Stratification of T2DM patients by HbA1c or duration of AD use
showed similar results (Table 1).
Severity of knee pain was rated by 327/387 (84.5%) patients
with knee OA, and the results were 5.1  2.0 [standard deviation
(SD)] and 4.8  2.2 in patients with and without T2DM, respectively.
Table 1
Association of prediabetes and type 2 diabetes mellitus (T2DM) with knee osteoarthritis (OA)a in patients stratified by HbA1c and duration of antihyperglycaemic drug (AD)
use.
No knee OA
(n = 2334)
n (%)
Knee OA
(n = 387)
n (%)
OR (95% CI)
unadjusted
OR (95% CI)
adjusted for BMI
OR (95% CI)
adjusted for
age/gender/BMI
OR (95% CI) fully
adjustedb
NGM 1383 (59.3) 182 (47.0) Reference Reference Reference Reference
Prediabetes 363 (15.6) 65 (16.8) 1.36 (0.99–1.85) 1.09 (0.80–1.49) 0.97 (0.70–1.35) 0.98 (0.70–1.37)
T2DM 588 (25.2) 140 (36.2) 1.81 (1.42–2.30) 1.22 (0.94–1.60) 1.11 (0.84–1.48) 0.96 (0.69–1.33)
HbA1c levels:
6.0% 94 (16.0) 17 (12.1) 1.37 (0.80–2.36) 1.07 (0.62–1.86) 1.00 (0.57–1.76) 0.84 (0.47–1.50)
6.1–7.0% 324 (55.1) 68 (48.6) 1.59 (1.18–2.16) 1.10 (0.80–1.52) 0.97 (0.69–1.37) 0.86 (0.59–1.26)
>7.0% 170 (28.9) 55 (36.2) 2.46 (1.75–3.46) 1.55 (1.07–2.25) 1.47 (0.99–2.17) 1.28 (0.83–1.98)
AD usec
Never 155 (26.4) 31 (22.1) 1.52 (1.00–2.30) 1.1 (0.67–1.60) 0.90 (0.57–1.40) 0.87 (0.55–1.38)
Past 24 (4.1) 6 (4.3) 1.90 (0.77–4.71) 1.2 (0.49–3.15) 1.10 (0.43–2.85) 0.95 (0.36–2.48)
Recent 25 (4.3) 5 (3.6) 1.52 (0.57–4.02) 1.3 (0.49–3.50) 1.16 (0.43–3.16) 1.04 (0.37–2.92)
Current 384 (65.3) 98 (70.0) 1.94 (1.48–2.54) 1.3 (0.96–1.74) 1.21 (0.88–1.66) 1.01 (0.70–1.47)
Duration of AD use
879 days 101 (26.3) 20 (20.4) 1.50 (0.91–2.49) 1.0 (0.61–1.74) 1.01 (0.59–1.73) 0.87 (0.49–1.55)
880–1645 days 97 (25.3) 23 (23.5) 1.80 (1.11–2.91) 1.2 (0.72–1.98) 1.13 (0.67–1.92) 0.99 (0.56–1.73)
1646–2939 days 96 (25.0) 25 (25.5) 1.98 (1.24–3.15) 1.3 (0.82–2.16) 1.26 (0.76–2.08) 1.05 (0.60–1.83)
>2939 days 90 (23.4) 30 (30.6) 2.53 (1.63–3.94) 1.6 (1.04–2.62) 1.45 (0.89–2.35) 1.17 (0.68–2.02)
a According to adapted American College of Rheumatology criteria: knee pain not due to accident experienced over at least four of the last six weeks and meeting at least
three of the following five criteria: age>50 years; morning stiffness lasting<30 min; bony tenderness; bony distortions; no palpable warmth in the knee; those with knee
prostheses were classified as knee OA.
b At time of inclusion by age, gender, BMI, education level, smoking status, alcohol use, systolic and diastolic blood pressure, a physically demanding occupation, history of
activities such as running and/or jumping, and use, 6 months prior to inclusion, of statins, diuretics, calcium-channel blockers, beta-blockers, renin–aldosterone–angiotensin
system (RAAS) inhibitors, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, bisphosphonates or systemic corticoids.
c Current users defined as having at least one recorded dispensing within 90 days of inclusion date; recent users defined as taking an AD 91–180 days before inclusion, but
not within 90 days of inclusion date; past users defined as stopping AD use>180 days before inclusion date; NGM: normal glucose metabolism.
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pain in either unadjusted (b: 0.28; P = 0.23) or adjusted (b: 0.04;
P = 0.88) models (Table S4; see supplementary materials associated
with this article online).
Discussion
Our present results demonstrate that patients with T2DM are
more likely to experience knee pain and knee OA. However, these
associations were no longer present after adjusting for BMI,
reflecting the importance of overweight in the relationship
between T2DM and knee pain or knee OA. In patients with knee
OA, there was no difference in severity of knee pain experienced by
T2DM patients compared with those without T2DM.
The association of T2DM with knee pain as reported in the
present study confirms the findings of previous studies [9,10]. The
association of T2DM with knee OA was strongly influenced by BMI,
suggesting that T2DM does not affect knee OA independently. The
inconsistency between results from the present study and other
previous studies may be due to methodological differences, such as
different definitions of OA, and the general difficulty of assessing
duration and date of onset of knee OA and T2DM. Also, the known
major role of overweight in knee OA might overrule (small)
metabolic effects, although this may not apply to OA in other joints,
such as those of the hand, where overweight is less likely to have
any effect.
Although T2DM patients experience knee pain more often
than those without T2DM, our study has shown that the severity
of the experienced knee pain in patients with knee OA does not
differ between subjects with and without T2DM. This may be
due to the fact that our included T2DM population was
relatively healthy, and their glucose metabolism was relatively
well controlled. Thus, the effects of any underlying biopatho-
logical mechanisms or of diabetic neuropathy may have been
limited.
Our study has several strengths. First, the Maastricht Study is
characterized by an extensive phenotyping approach, making itpossible to include a wide range of potential confounders. This
provides an opportunity to better assess the independent
association of T2DM with knee pain and knee OA. Second, as
the Maastricht Study was focused on T2DM and its comorbidities,
glucose metabolism status was highly accurately defined, render-
ing the risk of misclassification low. Third, this was the first study
to provide an insight into the different perception of severity of
knee pain between those with and without T2DM.
However, there were some limitations as well. Due to the cross-
sectional design of our study, causality cannot be assessed.
Furthermore, as there was no measurement of crepitus during
motion, the original ACR definition of clinical knee OA could not be
used [8]. Nevertheless, our adapted definition was more stringent
than the original (three out of five criteria were required compared
with three out of six criteria in the original definition). Thus, some
OA cases may have been misclassified as non-OA. However, such
misclassification would be expected to be non-differential,
resulting in a bias towards null. As a consequence, the effect of
T2DM on OA may have been underestimated. Finally, as is the case
in most studies, the date of onset and duration of T2DM are difficult
to determine. In the present study, an attempt was made to
approximate these data by stratifying T2DM patients by duration
of AD use. However, this approximation may not reflect the actual
date of disease onset as non-pharmacological lifestyle changes are
usually suggested first. Nevertheless, it does provide a specific
point in the course of the disease at which metabolic control can
only be achieved by pharmacological treatment. Duration of knee
pain or knee OA were not available and were therefore not
included in our analyses.
In conclusion, T2DM patients are more likely to experience knee
pain or have knee OA compared with patients with NGM, although
this seems to be mostly associated with overweight rather than a
metabolic effect, thereby emphasizing the importance of weight
reduction as a major factor in the treatment and prevention of knee
pain and knee OA. Furthermore, T2DM patients with knee OA do
not experience knee pain any differently from knee OA patients
without T2DM.
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